4.6 Article

An orthotopic skull base model of malignant meningioma

Journal

BRAIN PATHOLOGY
Volume 18, Issue 2, Pages 172-179

Publisher

WILEY
DOI: 10.1111/j.1750-3639.2007.00109.x

Keywords

bioluminescent imaging; IOMM-Lee; meningioma; orthotopic; skull base; xenografts

Funding

  1. NCI NIH HHS [P50 CA097257, P50CA097257] Funding Source: Medline
  2. NINDS NIH HHS [R03 NS054829, 1R03NS054829-01] Funding Source: Medline
  3. NATIONAL CANCER INSTITUTE [P50CA097257] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R03NS054829] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Meningioma tumor growth involves the subarachnoid space that contains the cerebrospinal fluid. Modeling tumor growth in this microenvironment has been associated with widespread leptomeningeal dissemination, which is uncharacteristic of human meningiomas. Consequently, survival times and tumor properties are varied, limiting their utility in testing experimental therapies. We report the development and characterization of a reproducible orthotopic skull-base meningioma model in athymic mice using the IOMM-Lee cell line. Localized tumor growth was obtained by using optimal cell densities and matrigel as the implantation medium. Survival times were within a narrow range of 17-21 days. The xenografts grew locally compressing surrounding brain tissue. These tumors had histopathologic characteristics of anaplastic meningiomas including high cellularity, nuclear pleomorphism, cellular pattern loss, necrosis and conspicuous mitosis. Similar to human meningiomas, considerable invasion of the dura and skull and some invasion of adjacent brain along perivascular tracts were observed. The pattern of hypoxia was also similar to human malignant meningiomas. We use bioluminescent imaging to non-invasively monitor the growth of the xenografts and determine the survival benefit from temozolomide treatment. Thus, we describe a malignant meningioma model system that will be useful for investigating the biology of meningiomas and for preclinical assessment of therapeutic agents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available